Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Research chair into Higher Education gets boost for five more years
2017-11-21

 Description: Prof Melanie Walker, Research chair into Higher Education gets boost for five more years Tags: Prof Melanie Walker, Research chair into Higher Education gets boost for five more years

Prof Melanie Walker, Director of the Centre for Research on
Higher Education and Development (CRHED).
Photo: Supplied

The research Chair in Higher Education and Human Development within the Centre for Research on Higher Education and Development (CRHED) at the University of the Free State has secured funding for another five years. It follows a favourable evaluation by the South African Research Chairs Initiative (SARChI) of the research project at the UFS. 

The Director of the Centre, Prof Melanie Walker, says she is delighted by the recognition of the Chair's hard work and significant productivity. “This new round of funding secures the centre and its activities for the next five years.” 

Under the auspices of the Chair, research is conducted on higher education, inequalities and social justice, and how or if universities foster the human capabilities and aspirations of students. In essence, the research studies whether higher education makes a difference to the lives of students, their families and communities. Prof Walker says the Chair's projects look at issues of access, participation and transitions into work, as well as gender, race and social class. The research uses quantitative and qualitative methods and includes a strand of participatory research projects with students.

Prof Walker says through the Chair research project, and the Centre, researchers have developed extensive international links and produced international quality research and publications. “We foster high-quality PhD graduates as a new generation of social science academics.” The Chair has in the first five years produced 10 PhDs and four master’s students. 

The project in the next five years will continue with its focus on higher education and human development research. Prof Walker says all the research efforts seek to contribute to more justice in society and universities and to contribute to debates, policy and practices in higher education and a scholarly knowledge base. 

The Research Chairs Initiative aims to improve the research capacity at public universities to produce high-quality postgraduate students, research and innovative outputs. The assessors looked at features such as the number of students the research entity had trained and how many publications the research team had produced. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept